Sonesitatug vedotin clinical trials
Also written AZD0901 and CMG901.
How each study uses sonesitatug vedotin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the sonesitatug vedotin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2025 (3)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 3 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 1
AstraZeneca (6) · Keymed Biosciences Co.Ltd (1) · Jeeyun Lee (1)
Often tested with
Tested in the same studies.
Rilvegostomig (3) · Trastuzumab deruxtecan (2) · Capecitabine (1) · Fluorouracil (1) · Leucovorin (1) · Oxaliplatin (1) · Docetaxel (1) · Volrustomig (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3
Studies that test sonesitatug vedotin.
- Nov 2026AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2Phase 2 · AstraZeneca
- Nov 2027A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal AdenocarcinomaPhase 2 · AstraZeneca
- Nov 2027Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaPhase 2 · AstraZeneca
Studies
Open first, then newest update. How each study uses sonesitatug vedotin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal AdenocarcinomaRecruitingPhase 2AstraZenecaNCT07069712Written as Sonesitatug Vedotin
- Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2RecruitingPhase 3AstraZenecaNCT07431281Written as Sonesitatug vedotin
- AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2RecruitingPhase 2AstraZenecaNCT06219941Written as AZD0901
- Perioperative Therapies in Locally Advanced Unresectable Gastric CancerRecruitingPhase 2Jeeyun LeeNCT06630130Written as Sonesitatug Vedotin
- Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaRecruitingPhase 2AstraZenecaNCT05702229Written as AZD0901
- AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2Active, not recruitingPhase 3AstraZenecaNCT06346392Written as AZD0901
- A Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2Active, not recruitingPhase 2AstraZenecaNCT07143604Written as AZD0901
- Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901CompletedPhase 1Keymed Biosciences Co.LtdNCT04805307Written as CMG901
Codes
What other systems call sonesitatug vedotin · ClinicalTrials.gg INT015808
- UNII (FDA) 96ZG83EF42SONESITATUG VEDOTINOne source FDA
- NCI Thesaurus C180413Sonesitatug VedotinOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 96ZG83EF42 | SONESITATUG VEDOTIN | One source FDA |
| NCI Thesaurus | C180413 | Sonesitatug Vedotin | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.